Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab and Lenvatinib Neoadjuvant Therapy for Non-Clear Cell RCC
NCT06129955Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT06129955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06129955.